Biological
Adenovirus Specific T- Lymphocytes
Adenovirus Specific T- Lymphocytes is a biological therapy with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
active_not_recruiting133%
recruiting267%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_1
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
NCT06909110
recruitingphase_1
Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections
NCT04722029
active_not_recruitingphase_1
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
NCT04364178
Clinical Trials (3)
Showing 3 of 3 trials
NCT06909110Phase 1
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
NCT04722029Phase 1
Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections
NCT04364178Phase 1
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3